NCT00375310 - Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2014

Conditions

Pancreatic CancerAdenocarcinoma of the Pancreas

Interventions

DRUG

Gemcitabine, Sorafenib

"Gemcitabine is given IV~Sorafenib is given orally of varying doses:~1. Sorafenib 200 mg po qd ( during combination therapy)~2. Sorafenib 400 mg po qd ( during combination therapy)~3. Sorafenib 400 mg po bid ( during combination therapy)"

PROCEDURE

Radiotherapy

1.8 Gy CTV daily for 5 weeks

Trial Locations (1)

46202

Indiana University Simon Cancer Center, Indianapolis